BRCA2, Polyclonal Antibody

Breast Cancer Susceptibility Protein 2; Early Onset; FANCB; FANCD1; FACD; FANCB; FAD1; FAD; FANCD1; BRCC2; OTTHUMP00000042401

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Affinity purified

100 ug (0.5 mg/ml) affinity purified rabbit anti-BRCA2 polyclonal antibody in phosphate buffered saline (PBS), pH 7.2, containing 30% glycerol, 0.5% BSA, 0.01% thimerosal.
Appearance: Colorless liquid

0.5 mg/ml (lot specific)

At -20 degree C
Shelf Life: 12 months

Small volumes of anti-BRCA2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Background: BRCA 1 and 2 are breast cancer susceptibility proteins that play a role in DNA damage, repair, cell cycle progression, transcription and apoptosis, etc. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. BRCA2 has been shown to be required for localization of Rad51 to sites of DSBs (double stranded breaks) in DNA. Cells lacking BRCA1 and BRCA2 cannot repair DSBs thromugh the Rad51-dependent process.

Western Blot (WB)

Western blotting (0.5-4 ug/ml). However, the optimal conditions should be determined individually. HeLa cell lysate can be used as a positive control.

384,225 Da

breast cancer 2, early onset

breast cancer type 2 susceptibility protein

Breast cancer type 2 susceptibility protein

FACD; FANCD1  [Similar Products]

BRCA2_HUMAN

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, Dec 2008]

BRCA2: involved in double-strand break repair and/or homologous recombination. May participate in S phase checkpoint activation. Interacts with RAD51 and DSS1. Interacts with ubiquitinated FANCD2. Interacts with PALB2, enables the recombinational repair and checkpoint functions. Interacts with WDR16. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer and may underlie susceptibility to uveal melanoma.

Protein type: Tumor suppressor; DNA repair, damage; Nuclear receptor co-regulator

Chromosomal Location of Human Ortholog: 13q12.3

Cellular Component: nucleoplasm; centrosome; protein complex; cytoplasm; BRCA2-MAGE-D1 complex; nucleus; secretory granule

Molecular Function: protein binding; H4 histone acetyltransferase activity; gamma-tubulin binding; histone acetyltransferase activity; protease binding; H3 histone acetyltransferase activity; single-stranded DNA binding

Biological Process: positive regulation of transcription, DNA-dependent; cell aging; cytokinesis; positive regulation of mitotic cell cycle; DNA repair; inner cell mass cell proliferation; regulation of cytokinesis; oocyte maturation; negative regulation of mammary gland epithelial cell proliferation; response to UV-C; double-strand break repair via homologous recombination; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; male meiosis I; nucleotide-excision repair; double-strand break repair; response to gamma radiation; replication fork protection; spermatogenesis; hemopoiesis; brain development; centrosome duplication; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; female gonad development; response to X-ray

Disease: Pancreatic Cancer, Susceptibility To, 2; Breast-ovarian Cancer, Familial, Susceptibility To, 2; Prostate Cancer; Breast Cancer; Medulloblastoma; Glioma Susceptibility 3; Tracheoesophageal Fistula With Or Without Esophageal Atresia; Fanconi Anemia, Complementation Group D1; Wilms Tumor 1

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.